Current Report Filing (8-k)
July 02 2021 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 1, 2021
ADVAXIS,
INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36138
|
|
02-0563870
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
9
Deer Park Drive, Suite K-1
Monmouth
Junction, NJ
|
|
08852
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609) 452-9813
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.001 per share
|
|
ADXS
|
|
Nasdaq
Capital Market
|
Preferred
Share Purchase Rights
|
|
-
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
Advaxis,
Inc. (the “Company”) held its further Reconvened 2021 Annual Meeting of Stockholders (the “Reconvened Annual Meeting”)
on July 1, 2021. At the Reconvened Annual Meeting, the following matter was submitted to a vote of stockholders:
|
1.
|
A
proposal to approve an amendment to the Amended and Restated Certificate of Incorporation (the “Charter”) to effect a
reverse stock split of the Company’s common stock at a ratio determined by the Board of Directors within a range of one-for-five
to one-for-fifteen, without reducing the authorized number of shares of our common stock, to be effected in the sole discretion of
the Board of Directors at any time within one year of the date of the 2021 Annual Meeting of Stockholders without further approval
or authorization of our stockholders (the “Reverse Stock Split Proposal”).
|
At
the Reconvened Annual Meeting, the Company’s stockholders did not approve the Reverse Stock Split Proposal.
Proposal
No. 5 – Proposal to Approve the Reverse Stock Split Proposal
The
vote to approve an amendment to the Charter to effect a reverse stock split of the Company’s common stock at a ratio determined
by the Board of Directors within a range of one-for-five to one-for-fifteen, without reducing the authorized number of shares of our
common stock, to be effected in the sole discretion of the Board of Directors at any time within one year of the date of the 2021 Annual
Meeting of Stockholders without further approval or authorization of our stockholders was as follows:
For
|
|
Against
|
|
Abstain
|
56,653,343
|
|
30,030,409
|
|
500,712
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
July
2, 2021
|
ADVAXIS,
INC.
|
|
|
|
|
By:
|
/s/
Kenneth A. Berlin
|
|
Name:
|
Kenneth
A. Berlin
|
|
Title:
|
President,
Chief Executive Officer and Interim Chief Financial Officer
|
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024